Core Insights - Cryoport, Inc. reported a strong Q3 2025 with a 15% year-over-year revenue growth from continuing operations, driven by significant contributions from commercial cell and gene therapies, which grew 36% to $8.3 million [2][8][17] - The company raised its full-year revenue guidance for 2025 to a range of $170 million to $174 million, reflecting confidence in ongoing growth and operational momentum [4][15] Financial Performance - Total revenue for Q3 2025 was $44.2 million, compared to $38.3 million in Q3 2024, marking a 15% increase [17] - Life Sciences Services revenue increased by 16% year-over-year to $24.3 million, while Life Sciences Products revenue grew by 15% to $20.0 million [17] - For the first nine months of 2025, total revenue reached $130.7 million, up from $115.3 million in the same period of 2024 [17] Segment Performance - Life Sciences Services accounted for 55% of total revenue in Q3 2025, with BioStorage/BioServices revenue rising 21% year-over-year [2][17] - Life Sciences Products represented 45% of total revenue, with a 15% increase in revenue compared to Q3 2024 [17] Operational Developments - The company launched new products, including next-generation dry vapor shippers with integrated condition monitoring solutions, enhancing its service offerings [3][16] - Cryoport expanded its global infrastructure with a new Global Supply Chain Center in Paris and plans for another in Santa Ana, California, expected to open in late 2026 [4][16] Clinical Trials and Market Position - As of September 30, 2025, Cryoport supported 745 global clinical trials, an increase of 54 trials from the previous year, with 83 in Phase 3 [6][7] - The company supported 19 commercial therapies, indicating a robust pipeline and market presence in the life sciences sector [6][8] Financial Metrics - Gross margin from continuing operations was 48.2% for Q3 2025, up from 45.5% in Q3 2024, reflecting improved operational efficiency [17] - Adjusted EBITDA from continuing operations was a negative $0.6 million for Q3 2025, an improvement from a negative $2.7 million in Q3 2024 [12][17] Cash Position - Cryoport held $421.3 million in cash, cash equivalents, and short-term investments as of September 30, 2025, providing a strong liquidity position for future investments [13]